original contributions nature publishing group Atherosclerotic renal artery stenosis (ARAS) is found increasingly in older patients, especially among those with coronary or peripheral vascular disease. [1] [2] [3] [4] It is frequently associated with hypertension and impaired renal function. [5] [6] [7] [8] it is not yet completely clear whether, in these situations, it has a causal role or is an associated finding. 9 Currently, there are mainly two therapeutic options for people with ARAS and hypertension and/or impaired renal function, that is, drug treatment or revascularization with percutaneous transluminal renal angioplasty (PTRA) and stent placement. 10 Some randomized controlled trials [11] [12] [13] have evaluated the impact of drug therapy and PTRA on blood pressure (BP) control and renal function modification. Metaanalyses 14,15 of these studies have shown that revascularization does not appear substantially superior to medical therapy in reducing BP and preventing worsening of renal function, though special conditions 16 should be taken into account.
Atherosclerotic renal artery stenosis (ARAS) is found increasingly in older patients, especially among those with coronary or peripheral vascular disease. [1] [2] [3] [4] It is frequently associated with hypertension and impaired renal function. [5] [6] [7] [8] However, it is not yet completely clear whether, in these situations, it has a causal role or is an associated finding. 9 Currently, there are mainly two therapeutic options for people with ARAS and hypertension and/or impaired renal function, that is, drug treatment or revascularization with percutaneous transluminal renal angioplasty (PTRA) and stent placement. 10 Some randomized controlled trials [11] [12] [13] have evaluated the impact of drug therapy and PTRA on blood pressure (BP) control and renal function modification. Metaanalyses 14, 15 of these studies have shown that revascularization does not appear substantially superior to medical therapy in reducing BP and preventing worsening of renal function, though special conditions 16 should be taken into account.
Some earlier 12, 13 and recent [17] [18] [19] randomized trials have also reported data about cardiovascular outcome in patients with ARAS undergoing different therapeutic strategies. A recent meta-analysis 20 evaluating all reports, [11] [12] [13] , [17] [18] [19] beyond confirming no substantial difference between PTRA and drug therapy about the impact on BP control and renal function, also reported no difference in all-cause mortality, heart failure, and stroke between patients treated with PTRA or medical therapy. At present, no study has performed an extensive analysis regarding nonfatal coronary events.
The aim of this study was to perform a meta-analysis of randomized controlled trials to compare the effect of PTRA and medical therapy on nonfatal myocardial infarction in patients with ARAS.
Methods
Literature review. We conducted a literature search through PubMed, Scopus, and ISI Web of Knowledge for randomized controlled trials in subjects with ARAS treated with revascularization or medical therapy from the beginning to December Background Cardiac outcome in patients with atherosclerotic renal artery stenosis (ARAS) undergoing percutaneous transluminal renal angioplasty (PTRA) or medical therapy is not yet completely clear. The aim of this study was to perform a meta-analysis of randomized controlled trials to compare the effect of PTRA and medical therapy on nonfatal myocardial infarction in patients with ARAS.
We searched for articles reporting cardiovascular outcome, including nonfatal myocardial infarction, in patients with renal artery stenosis randomized to PTRA with/without stenting or medical therapy.
results
Five studies were identified. The pooled population consisted of 1,159 subjects who experienced 56 nonfatal myocardial infarctions. When compared with medical therapy, the overall relative risk (RR) was 0.85 (95% confidence interval (CI) 0.51-1.42), P = 0.55, for PTRA. There was no significant difference between PTRA and medical therapy according to procedural characteristics (with/without stent placement), mean serum creatinine at follow-up (higher or lower than 2.0 mg/dl), and maximum follow-up length (> or <2 years).
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Renal Artery Stenosis and Therapy 2011. The terms used to identify studies were "renal artery stenosis", "medical therapy", "revascularization", "angioplasty", "stent", "randomized controlled trial", "hypertension", and "renal function". We also obtained recently presented data at national and international hypertension and nephrology congresses. Reference lists of included articles were also examined for additional studies. If necessary, supplementary data were obtained through personal contact with the investigators of the selected studies.
Study selection. Inclusion criteria for entry in the present metaanalysis were (i) randomized clinical trials evaluating patients with ARAS who were assigned to PTRA with/without stenting or medical therapy; (ii) assessment of cardiovascular outcome (nonfatal myocardial infarction in this specific setting).
The first literature search identified 22 studies, but only nine [11] [12] [13] [17] [18] [19] [21] [22] [23] could be eligible for the analysis. Of these, [11] [12] [13] [17] [18] [19] [21] [22] [23] five studies 12, 13, [17] [18] [19] could be included in the present meta-analysis. One study 11 was excluded because it did not report data about cardiovascular events, two 21, 22 because the medical therapy arm was lacking, and one 23 because the PTRA arm was lacking. Selection of publications is summarized in Figure 1 .
Main data from selected papers were independently extracted by three reviewers (S.D.P, A.M.P., and C.C).
Statistical analysis. Summary relative risk (RR) and 95% confidence interval (CI) were calculated between patients receiving PTRA or medical therapy, regarding the specific outcome of nonfatal myocardial infarction. We used the fixed or the random effects model according to the absence or presence of heterogeneity between studies. 24 Tests of heterogeneity were performed using the Cochrane Q statistic and I 2 statistic. 25 Individual studies were removed one at a time to evaluate the influence of that study on the pooled estimate. If the point estimate of the combined effect size with one study removed was outside the CI of the overall estimate with all available studies, then that specific study was considered to have an excessive influence on results. Subgroup meta-analysis, which is equivalent to meta-regression with categorical (or categorized) variables, was performed to analyze potential sources of heterogeneity. 26 A funnel plot, Begg and Mazumdar 27 rank correlation test and Egger's 28 regression test for funnel plot asymmetry were used to examine the likely presence of publication bias and small-study effect. Potential adjustment for missing studies was approached by Duval and Tweedie's trim and fill method. 29 Statistical significance was defined as P < 0.05 (two-tailed tests). Analyses were performed using the Comprehensive Meta-Analysis software, version 2 (Biostat, Englewood, NJ).
results
Main characteristics at baseline of study populations are reported in Table 1 . Globally, selected studies 12,13,17-19 included 1,159 subjects. Of these, 572 were randomized to PTRA and 587 to medical therapy. Inclusion criteria for entry in the studies were as follows: hypertension with monolateral or bilateral ARAS >50% in one study, 12 hypertension and normal or mildly impaired renal function with monolateral or bilateral ARAS >50% in another, 13 hypertension and renal failure with monolateral or bilateral ARAS >70% in another, 17 hypertension and impaired renal function with monolateral or bilateral ARAS >50% in another, 18 and hypertension or unexplained renal dysfunction with ARAS >50% in another. 19 The vast majority of subjects assigned to PTRA or medical therapy had ARAS ≥70%. Prevalence of bilateral ARAS ranged from 22% to 61%. Prevalence of coexisting coronary artery disease, when reported, ranged from 43% to 64%. As reported in Table 1 , though some characteristics and risk factors differed across the studies, they were similar between patients assigned to PTRA or medical therapy within each study.
Procedural characteristics, BP, and creatinine at follow-up, maximum follow-up length and events are reported in Table 2 . Stent placement was performed in three studies. [17] [18] [19] There was a substantial crossover from medical therapy to PTRA in only one study. 13 BP and serum creatinine at follow-up were not significantly different between patients treated with PTRA or medical therapy, though minimal differences were observed. At follow-up, mean serum creatinine values were lower than 2.0 mg/dl in four studies 12, 13, 17, 18 and >2.0 mg/dl in one study. 19 Maximum follow-up length was ≤2 years in two studies 13, 18 and >2 years in three studies. 12, 17, 19 As shown in Table 2 , globally, there were 56 nonfatal myocardial infarctions.
Where reported, 18, 19 use of antiplatelet and lipid-lowering drugs was similar between patients assigned to PTRA or medical therapy. original contributions
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We did not find significant heterogeneity between studies (Q = 0.76, P = 0.9 and all I 2 = 0%) and the fixed and random effects models gave the same results. Figure 2 gives the RR and 95% CI of the individual studies and of the overall analysis for the incidence of nonfatal myocardial infarction between patients assigned to PTRA or medical therapy. The overall RR was 0.85 (95% CI 0.51-1.42), P = 0.55, for PTRA vs. medical therapy.
Sensitivity analysis (Figure 3 ) indicated that none of the studies had a significant influential effect on the overall estimate.
When we explored for publication bias and small-study effect, the Begg and Mazumdar and Egger's tests were not significant (all two-tailed P > 0.2). When we applied Duval and Tweedie's trim and fill method, no study appeared missing on the left side of the mean effect, whereas one study appeared missing to the right side of the mean effect and the imputed point estimate was 0.88 (95% CI 0.53-1.46).
Though we did not find significant heterogeneity between studies, subgroup meta-analysis was performed in the attempt to find possible sources of differences. Random effects metaanalysis, according to procedural characteristics, mean serum creatinine at follow-up, and maximum follow-up length is reported in Table 3 . No significant differences were found between studies with or without stent placement, those with mean serum creatinine at follow-up higher or lower than 2.0 mg/dl, and those lasting more or less than 2 years.
discussion
This meta-analysis shows that future risk of nonfatal myocardial infarction is not significantly different between patients with ARAS and hypertension treated with PTRA or medical therapy alone.
Sensitivity analysis indicated that none of the selected studies had a significant influential effect on the overall estimate. When we explored for potential publication bias and smallstudy effect, formal tests were not significant, and if we applied the Duval and Tweedie's trim and fill method results remained the same or reinforced. Subgroup meta-analysis indicated that 12 van Jaarsveld et al. 13 Scarpioni et al. 17 Bax et al. 18 Astral For ref. 12 , BP at follow-up is calculated as a mean value between 12 months and the most recent contact, and creatinine at follow-up as a mean value between 6 months and the most recent contact. For Ref 18 , BP and creatinine at follow-up are those reported in the appendix Table of that manuscript. For ref. 19 , BP and creatinine at follow-up are calculated as a mean value from the year 1, 2, 3, 4, and 5 data. ref. 12 reports, in the text, one nonfatal myocardial infarction in patients treated with angioplasty and a group of four events in those treated with medical therapy (myocardial infarction and deaths or dialysis) from which one nonfatal myocardial infarction was extrapolated. Beyond mortality and other events, ref. 18 reports, in a table, three coronary artery disease events in each group that were considered as nonfatal myocardial infarctions. For refs. 13, 17, 19 , the number of nonfatal myocardial infarctions was provided by the authors. DBP, diastolic blood pressure; FU, follow-up; MT, medical therapy; NFMI, nonfatal myocardial infarction; PTRA, percutaneous transluminal renal angioplasty; SBP, systolic blood pressure.
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Renal Artery Stenosis and Therapy stent placement, mean serum creatinine at follow-up, and maximum follow-up length did not influence results. Finally, it should be remarked that patients undergoing PTRA also received drug therapy. All the abovementioned aspects give strength to our data. Some earlier meta-analyses 14, 15, 20 evaluated BP control and worsening of renal function in patients with ARAS treated with PTRA or medical therapy alone, but only one 20 of them also evaluated cardiovascular outcome. Kumbhani et al., 20 reported there was no difference between patients with ARAS treated with PTRA or medical therapy regarding all-cause mortality (RR = 0.96, 95% CI 0.74-1.25), congestive heart failure (RR = 0.79, 95% CI 0.56-1.13), and stroke (RR = 0.86, 95% CI 0.50-1.47). In the previous meta-analysis, 20 occurrence of nonfatal myocardial infarction was not evaluated. Results of our metaanalysis are essentially in line with those by Kumbhani et al. 20 and extend their findings indicating no difference between patients treated with PTRA or medical therapy concerning nonfatal cardiac events.
Some reasons could explain the lack of superiority of PTRA over medical therapy in preventing cardiovascular events in patients with ARAS and hypertension. First, ARAS could be an associated finding in an unquantifiable number of patients, i.e., part of them have essential hypertension with atherosclerotic 
Renal Artery Stenosis and Therapy lesions in various vascular districts, including renal arteries. In such a context, together with the systemic background, microvascular kidney disease, which is conditioned by longstanding high BP and other cardiovascular risk factors, could be more relevant than macrovascular renal artery disease in perpetuating high BP and in influencing global risk profile. Second, in this case, ARAS could be considered as a primary factor for hypertension; in the initial phase it activates the renin-angiotensin system; later it also impairs vasodilation in the renal and systemic microcirculation by the activation of oxidative stress, inflammation, fibrosis, and sympathetic activity. 10 Third, potential benefit of PTRA could be partly vanished by some procedural or postprocedural complications such as restenosis, distal embolization (which can also occur days or weeks after the procedure) 10 , and renal injury by radiological contrast medium or exposure to high BP after revascularization. 20 In the first hypothesis, PTRA does not appear to be the most appropriate therapy. In the second hypothesis, if PTRA is performed late during the natural history of ARAS, it may no longer produce benefit. In the third hypothesis, improvement in procedural characteristics are needed in the future. In any case, currently available data suggest there is no difference between PTRA and medical therapy in modifying major cardiovascular risk factors in patients with ARAS and hypertension and/or renal failure. It remains unclear whether different results could be obtained with PTRA in specific settings of patients, such as those with bilateral ARAS and/or flash pulmonary edema and/or rapidly deteriorating renal function and/or severe resistant hypertension. 30 This study has some limitations. First, cardiovascular events were considered as secondary endpoints in the selected studies; however, secondary endpoints have also been evaluated in other meta-analyses. 20, 31, 32 Second, the global number of nonfatal myocardial infarctions was not large and the CI around the overall RR tended to be wide; thus, further studies are needed to confirm our overall finding and results of subgroup meta-analyses should be interpreted with caution. Third, in one study 13 there was a large crossover from medical therapy to PTRA; however, considering the number of events in that study, 13 this aspect does not seem to have influenced overall result. Fourth, in one study, 18 28% of patients assigned to PTRA did not receive the procedure, and in another study, 19 17% of those assigned to revascularization did not receive PTRA; it is unclear whether this aspect might have affected results in the specific studies. Fifth, in three studies, 13, 18, 19 a small percentage of patients in both arms had ARAS <50% who probably did not benefit from PTRA, but the vast majority of studied subjects in both arms had ARAS >70% suggesting that the inclusion of aforesaid patients did not significantly influence results in the specific studies. Sixth, there is agreement, which is not evidence based, that patients with bilateral ARAS and/ or flash pulmonary edema and/or rapidly deteriorating renal function and/or severe resistant hypertension should undergo PTRA 30 ; as the abovementioned conditions were not analyzed separately in the included studies 12, 13, [17] [18] [19] and in this meta-analysis, our results cannot be applied to these specific groups of patients.
In conclusion, in patients with ARAS and hypertension, there is a lack of evidence supporting the superiority of PTRA over medical therapy in prevention of nonfatal myocardial infarction. Awaiting for the results of other ongoing clinical trials, [33] [34] [35] whose data will not be available for several more years, our analysis and an earlier 20 analysis suggest that optimal drug therapy for the control of BP and other major risk factor may be an appropriate approach in patients with ARAS and hypertension, except for special conditions, 16, 30 and that screening for ARAS in asymptomatic patients with atherosclerosis and hypertension and/or chronic renal failure may not be required.
